New generation of adjuvants for protection against disease and to combat bioterrorism

Sam D. Sanderson, Joseph A Vetro, Bala Vamsi Krishna Karuturi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter highlights the characteristics of traditional and non-traditional adjuvants, the advantages and disadvantages of their use in vaccines. It has so served to introduce the concept of molecular and host-derived adjuvants to improve immune outcomes while minimizing toxicities. A particular emphasis was placed on the generation of conformationally-restricted, response-selective agonists of the complement component C5a. These all appear to have therapeutic, manufacturing, and commercial potential. However, the development and use of such molecular adjuvants for vaccines represent only one approach put forward to meet the modern-day threats posed by antibiotic-resistant strains of bacteria and bioterrorism. It is clear that a well-organized and concerted worldwide effort that utilizes multiple approaches to develop novel adjuvant and vaccine designs will be required to overcome these growing threats to human and animal populations.

Original languageEnglish (US)
Title of host publicationNeuroimmune Pharmacology
PublisherSpringer International Publishing
Pages819-830
Number of pages12
ISBN (Electronic)9783319440224
ISBN (Print)9783319440200
DOIs
StatePublished - Jan 1 2016

Fingerprint

Bioterrorism
Vaccines
Complement C5a
Synthetic Vaccines
Anti-Bacterial Agents
Bacteria
Population
Therapeutics

Keywords

  • Antigen presenting cells
  • C5a
  • Complement
  • EP67
  • MPTP
  • Molecular adjuvant
  • Vaccines

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Sanderson, S. D., Vetro, J. A., & Karuturi, B. V. K. (2016). New generation of adjuvants for protection against disease and to combat bioterrorism. In Neuroimmune Pharmacology (pp. 819-830). Springer International Publishing. https://doi.org/10.1007/978-3-319-44022-4_48

New generation of adjuvants for protection against disease and to combat bioterrorism. / Sanderson, Sam D.; Vetro, Joseph A; Karuturi, Bala Vamsi Krishna.

Neuroimmune Pharmacology. Springer International Publishing, 2016. p. 819-830.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sanderson, SD, Vetro, JA & Karuturi, BVK 2016, New generation of adjuvants for protection against disease and to combat bioterrorism. in Neuroimmune Pharmacology. Springer International Publishing, pp. 819-830. https://doi.org/10.1007/978-3-319-44022-4_48
Sanderson SD, Vetro JA, Karuturi BVK. New generation of adjuvants for protection against disease and to combat bioterrorism. In Neuroimmune Pharmacology. Springer International Publishing. 2016. p. 819-830 https://doi.org/10.1007/978-3-319-44022-4_48
Sanderson, Sam D. ; Vetro, Joseph A ; Karuturi, Bala Vamsi Krishna. / New generation of adjuvants for protection against disease and to combat bioterrorism. Neuroimmune Pharmacology. Springer International Publishing, 2016. pp. 819-830
@inbook{6d0727f4782c444b88de8c575d9acf6a,
title = "New generation of adjuvants for protection against disease and to combat bioterrorism",
abstract = "This chapter highlights the characteristics of traditional and non-traditional adjuvants, the advantages and disadvantages of their use in vaccines. It has so served to introduce the concept of molecular and host-derived adjuvants to improve immune outcomes while minimizing toxicities. A particular emphasis was placed on the generation of conformationally-restricted, response-selective agonists of the complement component C5a. These all appear to have therapeutic, manufacturing, and commercial potential. However, the development and use of such molecular adjuvants for vaccines represent only one approach put forward to meet the modern-day threats posed by antibiotic-resistant strains of bacteria and bioterrorism. It is clear that a well-organized and concerted worldwide effort that utilizes multiple approaches to develop novel adjuvant and vaccine designs will be required to overcome these growing threats to human and animal populations.",
keywords = "Antigen presenting cells, C5a, Complement, EP67, MPTP, Molecular adjuvant, Vaccines",
author = "Sanderson, {Sam D.} and Vetro, {Joseph A} and Karuturi, {Bala Vamsi Krishna}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-44022-4_48",
language = "English (US)",
isbn = "9783319440200",
pages = "819--830",
booktitle = "Neuroimmune Pharmacology",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - New generation of adjuvants for protection against disease and to combat bioterrorism

AU - Sanderson, Sam D.

AU - Vetro, Joseph A

AU - Karuturi, Bala Vamsi Krishna

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This chapter highlights the characteristics of traditional and non-traditional adjuvants, the advantages and disadvantages of their use in vaccines. It has so served to introduce the concept of molecular and host-derived adjuvants to improve immune outcomes while minimizing toxicities. A particular emphasis was placed on the generation of conformationally-restricted, response-selective agonists of the complement component C5a. These all appear to have therapeutic, manufacturing, and commercial potential. However, the development and use of such molecular adjuvants for vaccines represent only one approach put forward to meet the modern-day threats posed by antibiotic-resistant strains of bacteria and bioterrorism. It is clear that a well-organized and concerted worldwide effort that utilizes multiple approaches to develop novel adjuvant and vaccine designs will be required to overcome these growing threats to human and animal populations.

AB - This chapter highlights the characteristics of traditional and non-traditional adjuvants, the advantages and disadvantages of their use in vaccines. It has so served to introduce the concept of molecular and host-derived adjuvants to improve immune outcomes while minimizing toxicities. A particular emphasis was placed on the generation of conformationally-restricted, response-selective agonists of the complement component C5a. These all appear to have therapeutic, manufacturing, and commercial potential. However, the development and use of such molecular adjuvants for vaccines represent only one approach put forward to meet the modern-day threats posed by antibiotic-resistant strains of bacteria and bioterrorism. It is clear that a well-organized and concerted worldwide effort that utilizes multiple approaches to develop novel adjuvant and vaccine designs will be required to overcome these growing threats to human and animal populations.

KW - Antigen presenting cells

KW - C5a

KW - Complement

KW - EP67

KW - MPTP

KW - Molecular adjuvant

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85045969289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045969289&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-44022-4_48

DO - 10.1007/978-3-319-44022-4_48

M3 - Chapter

AN - SCOPUS:85045969289

SN - 9783319440200

SP - 819

EP - 830

BT - Neuroimmune Pharmacology

PB - Springer International Publishing

ER -